Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP*

SYNAPSE Study Group

doi:https://doi.org/10.4193/Rhin22.053

Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP*

SYNAPSE Study Group

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Original language	English
Pages (from-to)	474-478
Number of pages	5
Journal	Rhinology
Volume	60
Issue number	6
DOIs	https://doi.org/10.4193/Rhin22.053
Publication status	Published - 2022

Access to Document

https://doi.org/10.4193/Rhin22.053

Cite this

@article{d4352a3e402e42bcb60d84395e5170a1,

title = "Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP*",

author = "Claus Bachert and Hellings, {Peter W.} and Lund, {Valerie J.} and Fokkens, {Wytske J.} and Claire Hopkins and Bhabita Mayer and Chan, {Robert H.} and Smith, {Steven G.} and Sousa, {Ana R.} and Rafael Alfonso-Cristancho and {SYNAPSE Study Group} and Shibing Yang",

note = "Funding Information: This study was funded by GlaxoSmithKline (GSK ID: 205687; ClinicalTrials.gov: NCT03085797). Funding Information: was funded by GSK.",

year = "2022",

doi = "https://doi.org/10.4193/Rhin22.053",

language = "English",

volume = "60",

pages = "474--478",

journal = "Rhinology",

issn = "0300-0729",

publisher = "University Hospital Utrecht",

number = "6",

}

TY - JOUR

T1 - Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP*

AU - Bachert, Claus

AU - Hellings, Peter W.

AU - Lund, Valerie J.

AU - Fokkens, Wytske J.

AU - Hopkins, Claire

AU - Mayer, Bhabita

AU - Chan, Robert H.

AU - Smith, Steven G.

AU - Sousa, Ana R.

AU - Alfonso-Cristancho, Rafael

AU - SYNAPSE Study Group

AU - Yang, Shibing

N1 - Funding Information: This study was funded by GlaxoSmithKline (GSK ID: 205687; ClinicalTrials.gov: NCT03085797). Funding Information: was funded by GSK.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85142624725&partnerID=8YFLogxK

U2 - https://doi.org/10.4193/Rhin22.053

DO - https://doi.org/10.4193/Rhin22.053

M3 - Comment/Letter to the editor

C2 - 36436220

SN - 0300-0729

VL - 60

SP - 474

EP - 478

JO - Rhinology

JF - Rhinology

IS - 6

ER -

Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP*

Access to Document

Other files and links

Cite this